Compare iShares Core MSCI EAFE ETF (IEFA) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Tempus AI — how do they compare? iShares Core MSCI EAFE ETF trades at $95.89 (market cap $191.47B), while Tempus AI trades at $70.5 (market cap $12.77B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 15× Tempus AI's market cap, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 41 Days and Tempus AI for 22 Days on average.
| IEFA | TEM | |
|---|---|---|
Market Cap | $191.47B | $12.77B |
Volume | 11,673,895 | 8,980,490 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $101.41 | $99.28 |
52-Week Low | $85.06 | $41.55 |
Typical Hold Time | 41 Days | 22 Days |
Enterprise Value | — | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA (iShares Core MSCI EAFE ETF) trades at $96.20, down 1.08% with bearish technical signals from moving averages but neutral oscillators. The ETF provides exposure to developed markets outside North America with $196 billion in assets under management. Recent comparisons highlight its competitive expense ratio of 0.07% and higher dividend yield versus peers like Schwab's SCHF and State Street's SPDW.
The fund faces headwinds from international market volatility and currency risks, though its size and diversification offer stability. Near-term performance may be influenced by global economic conditions and investor rotation away from concentrated U.S. tech exposure. Key support sits at $95 with resistance at $97.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
